Request Free Sample ×
China Car T Cell Therapy Market Research Report — Global Forecast till 2035 Infographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

China Car T Cell Therapy Market

ID: MRFR/Pharma/48116-HCR
200 Pages
Rahul Gotadki
Last Updated: April 06, 2026

China CAR T Cell Therapy Market Research Report By Therapeutic Area (Oncology, Autoimmune Diseases, Infectious Diseases), By Cell Source (Autologous, Allogeneic, Gene-Edited), By Indication (Acute Lymphoblastic Leukemia, Non-Hodgkin Lymphoma, Multiple Myeloma), andBy End-user (Hospitals, Research Institutes, Cancer Treatment Centers) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

China Car T Cell Therapy Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Chemicals and Materials, BY Therapeutic Area (USD Million)
  49.     4.1.1 Oncology
  50.     4.1.2 Autoimmune Diseases
  51.     4.1.3 Infectious Diseases
  52.   4.2 Chemicals and Materials, BY Cell Source (USD Million)
  53.     4.2.1 Autologous
  54.     4.2.2 Allogeneic
  55.     4.2.3 Gene-Edited
  56.   4.3 Chemicals and Materials, BY Indication (USD Million)
  57.     4.3.1 Acute Lymphoblastic Leukemia
  58.     4.3.2 Non-Hodgkin Lymphoma
  59.     4.3.3 Multiple Myeloma
  60.   4.4 Chemicals and Materials, BY End User (USD Million)
  61.     4.4.1 Hospitals
  62.     4.4.2 Research Institutes
  63.     4.4.3 Cancer Treatment Centers
  64. 5 SECTION V: COMPETITIVE ANALYSIS
  65.   5.1 Competitive Landscape
  66.     5.1.1 Overview
  67.     5.1.2 Competitive Analysis
  68.     5.1.3 Market share Analysis
  69.     5.1.4 Major Growth Strategy in the Chemicals and Materials
  70.     5.1.5 Competitive Benchmarking
  71.     5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  72.     5.1.7 Key developments and growth strategies
  73.       5.1.7.1 New Product Launch/Service Deployment
  74.       5.1.7.2 Merger & Acquisitions
  75.       5.1.7.3 Joint Ventures
  76.     5.1.8 Major Players Financial Matrix
  77.       5.1.8.1 Sales and Operating Income
  78.       5.1.8.2 Major Players R&D Expenditure. 2023
  79.   5.2 Company Profiles
  80.     5.2.1 Gilead Sciences (US)
  81.       5.2.1.1 Financial Overview
  82.       5.2.1.2 Products Offered
  83.       5.2.1.3 Key Developments
  84.       5.2.1.4 SWOT Analysis
  85.       5.2.1.5 Key Strategies
  86.     5.2.2 Novartis (CH)
  87.       5.2.2.1 Financial Overview
  88.       5.2.2.2 Products Offered
  89.       5.2.2.3 Key Developments
  90.       5.2.2.4 SWOT Analysis
  91.       5.2.2.5 Key Strategies
  92.     5.2.3 Bristol-Myers Squibb (US)
  93.       5.2.3.1 Financial Overview
  94.       5.2.3.2 Products Offered
  95.       5.2.3.3 Key Developments
  96.       5.2.3.4 SWOT Analysis
  97.       5.2.3.5 Key Strategies
  98.     5.2.4 Celgene (US)
  99.       5.2.4.1 Financial Overview
  100.       5.2.4.2 Products Offered
  101.       5.2.4.3 Key Developments
  102.       5.2.4.4 SWOT Analysis
  103.       5.2.4.5 Key Strategies
  104.     5.2.5 Amgen (US)
  105.       5.2.5.1 Financial Overview
  106.       5.2.5.2 Products Offered
  107.       5.2.5.3 Key Developments
  108.       5.2.5.4 SWOT Analysis
  109.       5.2.5.5 Key Strategies
  110.     5.2.6 Merck & Co. (US)
  111.       5.2.6.1 Financial Overview
  112.       5.2.6.2 Products Offered
  113.       5.2.6.3 Key Developments
  114.       5.2.6.4 SWOT Analysis
  115.       5.2.6.5 Key Strategies
  116.     5.2.7 AstraZeneca (GB)
  117.       5.2.7.1 Financial Overview
  118.       5.2.7.2 Products Offered
  119.       5.2.7.3 Key Developments
  120.       5.2.7.4 SWOT Analysis
  121.       5.2.7.5 Key Strategies
  122.     5.2.8 Janssen Pharmaceuticals (US)
  123.       5.2.8.1 Financial Overview
  124.       5.2.8.2 Products Offered
  125.       5.2.8.3 Key Developments
  126.       5.2.8.4 SWOT Analysis
  127.       5.2.8.5 Key Strategies
  128.     5.2.9 Bluebird Bio (US)
  129.       5.2.9.1 Financial Overview
  130.       5.2.9.2 Products Offered
  131.       5.2.9.3 Key Developments
  132.       5.2.9.4 SWOT Analysis
  133.       5.2.9.5 Key Strategies
  134.   5.3 Appendix
  135.     5.3.1 References
  136.     5.3.2 Related Reports
  137. 6 LIST OF FIGURES
  138.   6.1 MARKET SYNOPSIS
  139.   6.2 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA
  140.   6.3 CHINA MARKET ANALYSIS BY CELL SOURCE
  141.   6.4 CHINA MARKET ANALYSIS BY INDICATION
  142.   6.5 CHINA MARKET ANALYSIS BY END USER
  143.   6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
  144.   6.7 RESEARCH PROCESS OF MRFR
  145.   6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
  146.   6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  147.   6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
  148.   6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
  149.   6.12 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 (% SHARE)
  150.   6.13 CHEMICALS AND MATERIALS, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Million)
  151.   6.14 CHEMICALS AND MATERIALS, BY CELL SOURCE, 2024 (% SHARE)
  152.   6.15 CHEMICALS AND MATERIALS, BY CELL SOURCE, 2024 TO 2035 (USD Million)
  153.   6.16 CHEMICALS AND MATERIALS, BY INDICATION, 2024 (% SHARE)
  154.   6.17 CHEMICALS AND MATERIALS, BY INDICATION, 2024 TO 2035 (USD Million)
  155.   6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
  156.   6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
  157.   6.20 BENCHMARKING OF MAJOR COMPETITORS
  158. 7 LIST OF TABLES
  159.   7.1 LIST OF ASSUMPTIONS
  160.     7.1.1
  161.   7.2 China MARKET SIZE ESTIMATES; FORECAST
  162.     7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Million)
  163.     7.2.2 BY CELL SOURCE, 2025-2035 (USD Million)
  164.     7.2.3 BY INDICATION, 2025-2035 (USD Million)
  165.     7.2.4 BY END USER, 2025-2035 (USD Million)
  166.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  167.     7.3.1
  168.   7.4 ACQUISITION/PARTNERSHIP
  169.     7.4.1

China Chemicals and Materials Market Segmentation

Chemicals and Materials By Therapeutic Area (USD Million, 2025-2035)

  • Oncology
  • Autoimmune Diseases
  • Infectious Diseases

Chemicals and Materials By Cell Source (USD Million, 2025-2035)

  • Autologous
  • Allogeneic
  • Gene-Edited

Chemicals and Materials By Indication (USD Million, 2025-2035)

  • Acute Lymphoblastic Leukemia
  • Non-Hodgkin Lymphoma
  • Multiple Myeloma

Chemicals and Materials By End User (USD Million, 2025-2035)

  • Hospitals
  • Research Institutes
  • Cancer Treatment Centers

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓